EUVIMEDEUVIMED entdecken
Validierungsstudie

Validation of the US Food and Drug Administration's COVID‐19 Disease Severity Categorization for Use in Real‐World Data

Silvia Perez-Vilar iD, Wei Hua, Andrew Kwist iD, Yuxin Ma iD, Diane Dong, Rongping Zhang, Yong Ma, Andrea Chavez iD, Nina Huang, Virginia Sheikh, Yiyun Chiang iD, Cedric Salone und 8 weitere

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70252 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Silvia Perez-Vilar und 19 weiteren Autor:innen. Beteiligte Einrichtung: US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: COVID-19, Severity of Illness Index, United States Food and Drug Administration. Die Arbeit nennt 24 Literaturangaben. Gefördert von: US Food and Drug Administration, CMS HHS, VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The US Food and Drug Administration proposed a five‐level disease severity categorization for baseline COVID‐19 (asymptomatic, mild, moderate, severe, critical).

Aims

We conducted a pilot study aimed to validate the performance of the ICD‐10‐CM diagnosis code for COVID‐19 (U07.1) and operational definitions (code‐based algorithms) for each disease severity category in Medicare administrative data. Materials & Methods We sampled 250 community‐dwelling beneficiaries aged ≥ 18 years with a U07.1 code on an inpatient hospital or ambulatory claim between April 1, 2020 and June 18, 2022. We used stratified sampling based on care setting and COVID‐19 treatment status and adjusted results using sampling weights. Using medical records as the reference standard, we calculated positive predictive values (PPV) and 95% confidence intervals (CI). We conducted prespecified secondary analyses to improve algorithm performance by using refined disease definitions.

Results

We received medical records for 190 (77%) beneficiaries. Of these, 171 had a positive SARS‐CoV‐2 test result. The PPV of the COVID‐19 diagnosis code was 89% (CI: 83%–93%) overall, 88% (CI: 80%–93%) in the ambulatory setting, and 93% (CI: 82%–97%) in the inpatient setting. The operational definition for disease severity varied in performance by severity level and measurement strategy. The best performance was: PPV for asymptomatic and mild combined 69% (CI: 59%–77%), PPV for moderate 58% (CI: 34%–78%); PPV for severe 42% (CI: 27%–59%); and PPV for critical 85% (CI: 57%–96%).

Discussion

The code, U07.1, reliably identified beneficiaries with COVID‐19 in both ambulatory and inpatient settings. The operational definition to classify COVID‐19 disease severity notably improved performance when we implemented selected refinements.

Conclusion

Researchers should consider the moderate performance of the proposed operational definitions when using administrative claims data to assess COVID‐19 disease severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Severity of Illness IndexUnited States Food and Drug AdministrationHumansUnited StatesAgedFemaleMaleAged, 80 and overPilot ProjectsInternational Classification of DiseasesMedicareAlgorithmsMiddle Aged

Stichwörter der Autor:innen

COVID‐19Medicareelectronic health recordspositive predictive value

Autor:innen und Institutionen

  • US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Acumen LLC, Burlingame, California, USA.
  • US Department of Veterans Affairs, Hines, Illinois, USA.

ORCID-Profile: Silvia Perez-Vilar, Andrew Kwist, Yuxin Ma, Andrea Chavez, Yiyun Chiang, Yunfan Zhu, Suzann Pershing, Michael Wernecke, Fran E Cunningham, David J Graham

Förderung

  • US Food and Drug Administration
  • CMS HHS
  • VA
  • Centers for Medicare and Medicaid Services
  • U.S. Department of Veterans Affairs

Zitieren

APA

Perez-Vilar, S., Hua, W., Kwist, A., Ma, Y., Dong, D., Zhang, R., Ma, Y., Chavez, A., Huang, N., Sheikh, V., Chiang, Y., Salone, C., Pica, N., Zhu, Y., Pratt, N., Nadimpalli, G., Pershing, S., Wernecke, M., Cunningham, F. E., & Graham, D. J. (2025). Validation of the US Food and Drug Administration's COVID‐19 Disease Severity Categorization for Use in Real‐World Data. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70252

Vancouver

Perez-Vilar S, Hua W, Kwist A, Ma Y, Dong D, Zhang R, et al. Validation of the US Food and Drug Administration's COVID‐19 Disease Severity Categorization for Use in Real‐World Data. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70252

BibTeX
@article{PerezVilar2025,
  author = {Perez-Vilar, Silvia and Hua, Wei and Kwist, Andrew and Ma, Yuxin and Dong, Diane and Zhang, Rongping and Ma, Yong and Chavez, Andrea and Huang, Nina and Sheikh, Virginia and Chiang, Yiyun and Salone, Cedric and Pica, Natalie and Zhu, Yunfan and Pratt, Natasha and Nadimpalli, Gita and Pershing, Suzann and Wernecke, Michael and Cunningham, Fran E and Graham, David J},
  title = {Validation of the US Food and Drug Administration's COVID‐19 Disease Severity Categorization for Use in Real‐World Data},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70252}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche